6-K filed Jul 22, 2026 at 13:59 ET
Dr. Reddy's Q1 FY2027 results were sharply below prior year: revenue fell 6% YoY to Rs.80,705M, operating profit collapsed 78% to Rs.3,784M, and EPS dropped 69% to Rs.5.32. The US generics business was the primary drag, with North America revenue down 35% (41% in USD) due to price erosion and volume declines. Gross margin contracted 10.4pp to 46.5%, further pressured by a Rs.2,397M semaglutide inventory write-down. Growth in India (+17%), Emerging Markets (+31%), and Russia (+28%) partially offset the US decline but could not prevent a 69% profit plunge.